Ausgabe 5/2016
Inhalt (23 Artikel)
Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives
Ronaldo A. Ribeiro, Carlos W. S. Wanderley, Deysi V. T. Wong, José Maurício S. C. Mota, Caio A. V. G. Leite, Marcellus H. L. P. Souza, Fernando Q. Cunha, Roberto C. P. Lima-Júnior
Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas
Michael J. Nathenson, Edward Sausville
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors
John Sarantopoulos, Sanjay Goel, Vincent Chung, Pamela Munster, Shubham Pant, Manish R. Patel, Jeffrey Infante, Hussein Tawbi, Carlos Becerra, Justine Bruce, Fairooz Kabbinavar, A. Craig Lockhart, Eugene Tan, Shu Yang, Gary Carlson, Jeffrey W. Scott, Sunil Sharma
Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment
Kevin R. Kelly, Nashat Gabrail, Steven Weitman, John Sarantopoulos, Anthony J. Olszanski, William Edenfield, Jurgen Venitz, Guru Reddy, Allen Yang, Steven J. Hasal, A. Craig Lockhart
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience
Naohiro Oda, Katsuyuki Hotta, Hiroshige Yoshioka, Kenichiro Kudo, Eiki Ichihara, Yuka Kato, Kiichiro Ninomiya, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Akiko Sato, Nagio Takigawa, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura
A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer
Boram Han, Joo Young Jung, Hyeong Su Kim, Ji Woong Cho, Kab Choong Kim, Hyun Lim, Ho Suk Kang, Hong Il Ha, Min-Jeong Kim, Jung Hoon Kim, Dae Ro Choi, Geundoo Jang, Jung Han Kim, Hunho Song, Dae Young Zang
Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors
Martin J. Edelman, Rena Lapidus, Josephine Feliciano, Miroslav Styblo, Jan H. Beumer, Tao Liu, Jogarao Gobbru
Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors
Martin J. Edelman, Rena Lapidus, Josephine Feliciano, Miroslav Styblo, Jan H. Beumer, Tao Liu, Jogarao Gobburu
JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo
Cong Wang, Ran Wang, Kairui Zhou, Saiqi Wang, Junwei Wang, Hongge Shi, Yinhui Dou, Dongxiao Yang, Liming Chang, Xiaoli Shi, Ying Liu, Xiaowei Xu, Xiujuan Zhang, Yu Ke, Hongmin Liu
Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia
Stine Nygaard Nielsen, Kathrine Grell, Jacob Nersting, Thomas Leth Frandsen, Lisa Lyngsie Hjalgrim, Kjeld Schmiegelow
Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors
Yosuke Tamura, Hiroshi Nokihara, Kazunori Honda, Yuko Tanabe, Hajime Asahina, Yasuhide Yamada, Sotaro Enatsu, Raffael Kurek, Noboru Yamamoto, Tomohide Tamura
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
Wijith Munasinghe, Sven Stodtmann, Anthony Tolcher, Emiliano Calvo, Michael Gordon, Mathilde Jalving, Judith de Vos-Geelen, Diane Medina, Dennis Bergau, Silpa Nuthalapati, David Hoffman, Stacie Shepherd, Hao Xiong
Population pharmacokinetic–pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer
Masato Fukae, Yoshimasa Shiraishi, Takeshi Hirota, Yuka Sasaki, Mika Yamahashi, Koichi Takayama, Yoichi Nakanishi, Ichiro Ieiri
The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells
Xu Wang, Bo Yang, Baojing Ma
Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats
Alexandre Iarkov, Doreen Appunn, Valentina Echeverria
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma
Soushi Ibata, Tsutomu Sato, Hiroyuki Kuroda, Yasuhiro Nagamachi, Satoshi Iyama, Akihito Fujimi, Yusuke Kamihara, Yuichi Konuma, Masahiro Yoshida, Ayumi Tatekoshi, Akari Hashimoto, Hiroto Horiguchi, Kaoru Ono, Kazuyuki Murase, Kohichi Takada, Koji Miyanishi, Masayoshi Kobune, Yasuo Hirayama, Junji Kato
Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia
Savitha Varatharajan, John C. Panetta, Ajay Abraham, Sreeja Karathedath, Ezhilpavai Mohanan, Kavitha M. Lakshmi, Nancy Arthur, Vivi M. Srivastava, Sandeep Nemani, Biju George, Alok Srivastava, Vikram Mathews, Poonkuzhali Balasubramanian
A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors
Hanna Bailey, Jordan P. McPherson, Erin B. Bailey, Theresa L. Werner, Sumati Gupta, Julia Batten, Guru Reddy, Gajanan Bhat, Sunil Sharma, Neeraj Agarwal
Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma
Saeed Zavareh, Milad Mahdi, Soheyla Erfanian, Hamid Hashemi-Moghaddam
Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma
Jong-Ho Kim, In-Gu Do, Kyungeun Kim, Jin Hee Sohn, Hong Joo Kim, Woo Kyu Jeon, Sung Ryol Lee, Byung Ho Son, Jun Ho Shin, Heerim Nam, Heon-Ju Kwon, Mi Sung Kim, Hyun Pyo Hong, Ginette Serrero, Dong-Hoe Koo
Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients
Victoria J. Forster, Frederik W. van Delft, Susan F. Baird, Shona Mair, Roderick Skinner, Christina Halsey
Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?
Nuggehally R. Srinivas
15-0600-Dr. Fox’s response to letter to the editor
Elizabeth Fox, Frank M. Balis